Odyssean LLC’s Corcept Therapeutics CORT Stock Holding History

Odyssean LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Hold	14,271	–	–	0.2%	176
2026 Q1	$575K	Buy	14,271 +7,688	+117%	+$287K	0.21%	173
2025 Q4	$229K	Buy	+6,583	New	+$517K	0.16%	214

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Odyssean LLC's CORT Position: Q2 2026 in Review

Odyssean LLC held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 14,271 shares worth $1.24M. The position accounts for 0.2% of the portfolio, ranked #176.

Odyssean LLC first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Odyssean LLC held 14,271 shares of Corcept Therapeutics worth $1.24M as of Q2 2026.
Odyssean LLC left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.2% of Odyssean LLC's portfolio in Q2 2026, its #176 holding.
Odyssean LLC first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Odyssean LLC's 13F filing for Q2 2026, filed 14 Aug 2026.